37748-09-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Formylphenoxyacetic acid is used as an intermediate in the synthesis of various pharmaceuticals for its ability to undergo a variety of chemical reactions. Its reactive formyl group allows for the creation of diverse drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 3-formylphenoxyacetic acid is used as a building block in the development of new agrochemicals. Its reactivity and structural properties contribute to the design of effective compounds for agricultural use.
Used in Dye Industry:
3-Formylphenoxyacetic acid is utilized in the synthesis of dyes due to its potential to form a range of colored compounds. This makes it a valuable component in the production of various dyes for different applications.
Used in Cancer Research:
3-Formylphenoxyacetic acid has been studied for its potential use in the treatment of certain medical conditions, particularly in the field of cancer research. Its unique structure and reactivity may contribute to the development of novel therapeutic agents against cancer.
Used in Organic and Medicinal Chemistry:
Due to its unique structure and reactivity, 3-formylphenoxyacetic acid has potential applications in organic and medicinal chemistry. It can be used to explore new chemical reactions and synthesize compounds with potential applications in various fields.

InChI:InChI=1/C9H8O4/c10-5-7-2-1-3-8(4-7)13-6-9(11)12/h1-5H,6H2,(H,11,12)

Upstream product

• 100-83-4 meta-hydroxybenzaldehyde 
• 79-11-8 chloroacetic acid 
• 37748-10-0 methyl (3-formylphenoxy)acetate 
• 186191-14-0 potassium salt of 3-(carboxymethoxy)benzaldehyde 
• 51264-68-7 ethyl 2-(3-formylphenoxy)acetate 
• 79-08-3 bromoacetic acid 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 1878-61-1 3-carboxyphenoxyacetic acid 
• 92643-96-4 3-carboxymethoxy-cinnamic acid 
• 875801-92-6 {3-[(E)-2-(1,3-Dimethyl-5-nitro-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidin-4-yl)-vinyl]-phenoxy}-acetic acid 
• 208251-96-1 (3-formylphenoxy)acetic acid benzyl ester 
• 84214-33-5 {3-[(1Z,4Z,9Z,15Z)-10,15,20-Tris-(3-carboxymethoxy-phenyl)-porphyrin-5-yl]-phenoxy}-acetic acid 
• 292173-97-8 2-(3-((4-oxo-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-5-ylidene)methyl)phenoxy)acetic acid 
• 727396-68-1 3-(tert-butyloxycarbonylmethylaminocarbonylmethoxy)-benzaldehyde 
• 1449505-16-1 tert-butyl 4-(2-(3-formylphenoxy)acetyl)piperazine-1-carboxylate 
• 1449505-17-2 3-(2-oxo-2-(piperazin-1-yl)ethoxy)benzaldehyde 
• 1449505-18-3 3-(2-(4-(2-hydroxypropyl)piperazin-1-yl)-2-oxoethoxy)benzaldehyde 
• 51264-68-7 ethyl 2-(3-formylphenoxy)acetate 

Relevant academic research and scientific papers

NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS)

The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.

OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

Heterocyclic analogs of prostaglandines: IV. Synthesis of 3,7-interphenylene 3,10(11)-dioxa-13-azaprostanoids and 9-oxa-7-azaprostanoids based on tetronic acid and aromatic aldehydes

An approach was developed to the synthesis of stable in metabolism 3,7-interphenylene 3,10-dioxa-13-aza-and 3,11-dioxa-13-azaprostanoids, and also 9-oxa-7-azaprostanoids with interphenylene and terminal phenyl fragments in the ω-chain based on 3-(alkoxybenzylidene)-and 3-(3-phenylallylidene) tetrahydrofuran-2,4-diones obtained by Knoevenagel condensation of tetronic acid with alkoxy-substituted aromatic aldehydes and cinnamic aldehyde.

Development of an enzyme-linked immunosorbent assay for the pyrethroid insecticide cyhalothrin

A competitive enzyme-linked immunosorbent assay (ELISA) was developed for detection of the pyrethroid insecticide cyhalothrin. Three haptens with an amine or propanoic acid terminus were synthesized and then conjugated with bovine serum albumin to give immunogens. Eight polyclonal antisera produced by rabbits were screened for titers and affinity using three different coating antigens. The antiserum CWB-C had the highest affinity with cyhalothrin and a low affinity with fenvalerate, fenpropathrin, deltamethrin, and fluvalinate. The half-maximum inhibition concentration for cyhalothrin was 37.2 μg/L, and the limit of detection was 4.7 μg/L. The recoveries of different concentrations of cyhalothrin (0.1-2500 μg/L) from fortified tap water, well water, and wastewater samples as determined with the ELISA were 81-114%.

Asymmetric synthesis of polymer-supported cyanohydrin acetates

A bimetallic titanium(salen) complex has been used to catalyze the asymmetric addition of potassium cyanide to aldehydes attached to Wang resin giving polymer supported cyanohydrin propionates with up to 91% enantiomeric excesses.

6-aryl pyrazolo?3,4-D! pyrimidin-4-ones and compositions and method of use thereof

6-Aryl pyrazolo?3,4-d!pyrimidin-4-one derivatives, pharmaceutical compositions containing them and methods for effecting c-GMP-phosphodiesterase inhibition and for treating heart failure and/or hypertension.

Porphyrin synthesis in surfactant solution: Multicomponent assembly in micelles

A synthesis of meso-substituted porphyrins in anionic sodium dodecyl sulfate micelles has been developed. Polar, functionalized aromatic aldehydes condense reversibly with pyrrole in the micellar phase. Oxidation of the porphyrinogen then provides functionalized porphyrins in yields of 10-48%. Hydrophobic aldehydes condense irreversibly to give low yields at practical substrate concentrations. Synthesis in D2O solution results in per-β-deuterated porphyrins. A two-phase model is used to rationalize the dependence of porphyrin yield on reactant and surfactant concentration. Micelles are viewed as potential wells which promote porphyrinogen assembly by binding products more tightly than reactants.

1,4-dihydropyridine derivatives

Compounds a formula (I) STR1 wherein the substituents and symbols have the meanings given in the specification, are new compounds with marked cardiovascular activity.

[(4-phenyl-1,3-dioxan-cis-5-yl)alkyl]phenylalkanoic acid derivatives

The invention concerns novel [(4-phenyl-1,3-dioxan-cis-5-yl)alkyl]phenylalkanoic acids of the formula I wherein Ra and Rb are a variety of substituents including alkyl, alkenyl, halogenoalkyl, phenyl and benzyl, or together form polymethylene; Rc is hydro